upgrad rate gilead outperform
increas price target follow updat
manag industri confer last week san francisco
upgrad base think stabl hcv
trend expect trough earn
expect multipl expans growth beyond increment
growth view come taf base regimen hiv
inhibitor filgotinib rheumatoid arthriti ra ulcer
inhibitor selonsertib cell therapi platform cancer led
depend car-t therapeut yescarta
review hepat hcv product trend suggest
aggreg sale reach trough level global
declin like off-set hiv product
growth continu improv
taf base regimen competit pressur continu
mavyret expect price stabil
market share stabil predict pattern
new patient start believ mavyret competit
price market share dynam expect view
guidanc potenti clear event stock
focu expect rotat growth beyond trough
earn view yescarta broader cell therapi opportun
filgotinib inflammatori diseas separ drug class
non-alcohol steatohepat nash credibl growth driver
key valu inflect point expect next
month believ categori could exceed
sale ultim well posit gain domin
posit
establish
infrastructur reimburs
launch car-t therapeut yescarta expect
proceed deliber pace see take leadership
subsequ cell therapi drive ultim outpati
dose paradigm feedback cell therapi center suggest
impact alreadi felt term expans
acceler key clinic trial view acquisit
cell design lab potenti transform deal
next-gener switch technolog control cell multi-
final prospect filgotinib inflammatori diseas
selonsertib nash view long term safeti experi
filgotinib differenti establish effect improv
fibrosi grade differenti selonsertib expect posit
phase data next month drive signific
upsid share suggest nash could big hcv
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
non-gaap ep exclud stock-bas compens reflect adjust
compani prioriti stock list
compani data secur llc estim reuter
outlook focus hcv/hiv cell therapi pipelin progress
gilead host analyst meet last week san francisco industri confer
discuss compani initi key area focu includ hiv hcv cell therapi
follow present industri confer monday
continu hiv franchis growth expect partial off-set hcv declin
hiv franchis note hiv continu growth stori note dramat
prefer patient taf contain regimen genvoya odefsey descovi also note
grow use truvada prep use peopl us addit phase studi
descovi prep fulli enrol ahead schedul studi event-driven data readout
expect approxim year
taf-bas combin hiv continu drive switch busi market expans
current program hiv focus new modal long act inject
infrequ quarterli molecul
treatment-resist hiv hiv
highlight bictegravir/f/taf smallest non-boost integrase-contain singl
regimen demonstr resist across phase studi favor renal
bone profil could potenti better serv age hiv popul launch expect
see potenti cannib current taf busi launch b/f/taf
see signific opportun target non-boost daili integras inhibitor tivicay/triumeq
busi note b/f/taf avoid need hla hbv resist test
rel stabil hcv trend emerg term price market share
although new start continu declin
respect hcv see sale continu major busi compani
expect see greater hcv product sale stabil full impact abbv mavyret
occur reiter compon approach hcv guidanc dose durat market share
price patient-start note flat price elimin issu vs week therapi
price reach equilibrium contract cycl complet respect patient
share acknowledg mavyret enjoy success launch ascrib bulk success
reflect manag medicaid market mavyret displac zepati commerci
market remain confid success driven comprehens hcv portfolio final patient-
start expect continu declin million infect individu remain untreat
emerg pipelin focu filgotinib multipl nash asset next-gener cell
emphas three key area pipelin non-alcohol steatohepat nash specif
fibrosi autoimmun diseas focu inhibitor filgotinib cell therapi focu
leverag recent kite acquisit
initi focu nash advanc fibrot patient
first-in-class apoptosi signal-regul kinas inhibitor selonsertib selonsertib
advanc agent two on-going phase studi nash fibrosi
respect fibrosi studi expect complet enrol later januari top-lin
week data follow month later trial primari endpoint trial
stage reduct fibrosi score worsen na compon score use studi
valid non-invas test liver fibrosi note test consid effect diagnosi
fibrosi stage role monitor chang fibrosi score remain unproven also
evalu combin therapi three pair triplet proof concept data expect later
year expect defin best combin develop
addit detail nash pipelin suggest optim posit differenti clinic
three pipelin program nash acetyl-coa carboxylas inhibitor target
de novo lipogenesi fxr farnesoid receptor agonist target bile acid signal
report phase data nash american associ studi
phase studi enrol patient clinic diagnosi non-alcohol fatti liver
diseas nafld mri-pdff mri proton densiti fat fraction greater mre magnet
reson elastographi greater kpa biopsi consist nash fibrosi patient
random receiv mg mg placebo daili oral week
mg demonstr clinic meaning improv hepat steatosi fat build-up
liver measur mri-pdff week mg demonstr reduct mri-
pdff baselin vs reduct placebo mri-pdff respons rate defin
greater reduct mri-pdff mg group vs
placebo group mg also demonstr signific improv
serum marker fibrosi reduct baselin vs reduct placebo
mg demonstr statist signific differ placebo endpoint
evalu includ liver stiff fibroscan liver stiff mre serum alt piii-np although
numer trend dose-depend reduct alt piii-np despit reduct
piii-np score chang consist three fibrosi marker piii-np
hyaluron acid lower mg dose demonstr statist signific
differ placebo endpoint test
treatment associ increas triglycerid tg week patient
mg mg group experienc increas tg baselin vs decreas
placebo group asymptomat grade tg elev greater mg/dl
observ patient mg group patient mg group patient
tg elev continu treatment achiev tg less mg/dl either
spontan fibrat fish oil treatment describ safe well-toler
plan conduct addit studi evalu monotherapi combin approach
formerli fxr agonist acquir januari
up-front payment addit mileston potenti total note
intercept fxr agonist ocaliva bile acid analog wherea bile acid analog
random phase studi mg mg daili vs placebo week nash
patient initi decemb on-going primari complet studi
januari
selonsertib formerli first-in-class inhibitor activ nash
correl fibrosi
report top-lin data phase trial selonsertib monotherapi combin
compani lysyl oxidase-lik inhibitor simtuzumab patient nash octob
present full data aasld meet novemb
open label phase trial random subject biopsy-proven nash fibrosi
score one arm selonsertib qd simtuzumab selonsertib qd simtuzumab
simtuzumab alon simtuzumab dose weekli subcutan inject
endpoint includ chang fibrosi score review blind central pathologist progress
selonsertib demonstr better result dose demonstr better result
singl agent simtuzumab simtuzumab behav like placebo differ
specif patient selonsertib patient selonsertib
achiev stage greater fibrosi improv week compar simtuzumab
patient demonstr worsen fibrosi stage respect rate
cirrhosi progress selonsertib mg mg simtuzumab arm
respect mri-pdff respons rate defin greater reduct mri-pdff
selonsertib mg selonsertib mg simtuzumab mre respons rate
defin greater reduct liver stiff selonsertib mg
selonsertib mg simtuzumab
note selonsertib well toler dose relat increas treatment-emerg
mention initi two phase studi selonsertib nash stellar stellar
addit combin drug candid also underway
stellar studi evalu selonsertib mg mg vs placebo patient nash
bridg fibrosi co-primari endpoint includ proport patient achiev
stage greater improv fibrosi accord nash clinic research network crn
classif without worsen nash week event-fre surviv ef assess
time first clinic event week stellar studi start februari primari
complet expect januari
stellar studi ident design stellar studi except patient enrol
nash compens cirrhosi stellar studi start januari enrol
stellar expect complet end januari primari complet
stellar studi expect januari
approach phase result inhibitor filgotinib
inflamm pipelin anchor inhibitor filgotinib phase test
rheumatoid arthriti ra crohn diseas ulcer coliti cd/uc sever exploratori studi
on-going indic phase ra program includ finch trial evalu filgotinib
methotrex nave patient inadequ respond biolog inadequ respond
data latter trial expect cd/uc enrol cohort biolog experienc
biolog nave patient believ filgotinib may superior safeti profil jak
inhibitor highlight close patient year experi darwin long-term extens
phase ra trial encourag emerg safeti profil note singl case deep vein
thrombosis/pulmonari embol importantli design ra program includ blind
long term extens dose ensur filgotinib safeti fulli vet
cell therapi launch expect proceed cautious yescarta broad pipelin
yescarta cell therapi launch note launch in-lin kite
expect yescarta roll-out diffus
lymphoma dlbcl slow due
requir train certif process ensur toxic manag ensur high
degre custom satisfact believ key engend loyalti competit emerg
date cancer center certifi goal reach institut
respons treat cover patient dlbcl patient mix describ
commerci plan medicar highlight durabl respons advanc dlbcl
observ studi present recent american societi hematolog
meet highlight increment benefit
kite
team yescarta launch gild experi launch sever drug europ includ
year experi ambisom bone marrow transplant center describ provid critic
tactic strateg initi ahead yescarta launch later
yescarta studi highlight includ on-going studi yescarta combin
antibodi dlbcl popul consist recent open zuma-
random studi line dlbcl compar high dose chemotherapi without autolog
hematopoiet stem cell transplant versu yeacarta also highlight anti-b cell
matur antigen bcma car-t first dose cohort complet plan open
registr trial
futur direct car-t develop includ increas use autom effici
manufactur new synthet biolog tumor target make cellular therapi safer
effect allogen cell therapi shelf use note assembl
dedic team develop allo-car-t goal compar allo-bcma car-t
yescarta note area cell therapi move rapidli driven scientif
advanc compani embrac new technolog particularli import
continu work initi kite solid tumor
organ
price target
arriv price target appli multipl ep estim risk
includ continu slow hcv patient volum emerg credibl competit threat merck
particular failur key pipelin program hbv nash failur secur meaning revenu
opportun
expect stabil hcv trend visibl trough earn offset growth hiv product
emerg pipelin focus cell therapi cancer immunolog nash support out-performance
larg cap global commercial-stag biotechnolog compani discov develop small
molecul biolog drug global leadership hiv hcv expand beyond infecti
diseas liver diseas oncolog inflammation/fibrot diseas
